Allergic Asthma Therapeutic Market

Allergic Asthma Therapeutic Market Size

The global allergic asthma therapeutic market was valued at USD 7,046.26 million in 2025, is estimated to reach USD 7,230 million in 2026, and is projected to reach USD 8,878 million by 2034, growing at a CAGR of 2.60% from 2026 to 2034.

MARKET DRIVERS

An increase in pollution levels is one of the major factors driving the growth of the allergic asthma therapeutics market. Nowadays due to rapid industrialization and globalization there is an increase in the level of pollution day by day which causes a rapid increase in respiratory diseases and also the long-term heavy disease such as allergic asthma, In 2022 about 66 million tons of pollution were emitted into the atmosphere, due to these emitted pollutant there is an increase in the respiratory diseases such as allergic asthma thus increase in pollution level causes increase In the incidence of allergic asthma which causes need of proper care and therapies, air pollution have negative impact on asthma causes decrease in lung function, which later need proper therapy for the treatment of allergic asthma which boosting the growth of allergic asthma therapeutic market during forecasted period.

The increasing prevalence of chronic respiratory disorders is another critical factor driving the growth of the allergic asthma therapeutics market. Approximately 763 million people had a chronic respiratory disorder in 2022, Asthma is considered one of the most critical disorders worldwide and this has particularly driven the need for advanced therapeutics for asthma treatment. The sedentary lifestyle, changes in diet, and increased exposure to indoor allergens contribute to an increase in the prevalence of allergic asthma, which needs advanced therapies to treat properly thus this factor also helps in boosting the market growth during the forecasted period.

The another driver driving the growth of the allergic asthma therapeutic market is the advancement in medical research and technology led to the development of innovative and targeted options for allergic asthma. Many pharmaceutical companies now invested more in research and development to discover new medications, and inhalers that can provide symptom control and improve the quality of life for patients with allergic asthma. Due to innovation in technologies and advanced therapeutic application help in treatment of the allergic asthma and proper diagnosis and treatment of allergic asthma. This advancement in technologies and treatment options boosted the growth of the therapeutic market for allergic asthma. For the proper diagnosis and treatment of diseases need the use of advanced technologies for the proper treatment of allergic asthma, nowadays there is an increase in the innovation of techniques for proper treatment of diseases this causes boosting the growth of the market during the projected period.

Other significant factors propelling the growth of the allergic asthma therapeutic market are a worldwide increase in patients with various types of allergies, an increase in the level of environmental pollution, growing demand for clinics, research centers, and hospitals, growing demand for cost-effective treatment are some of the key driver boosting the growth of allergic asthma therapeutics market.

MARKET RESTRAINTS

Although many elements are boosting the market for treatments for allergic asthma, there are also some factors preventing its growth. The high cost of allergic asthma treatment can make it unaffordable for some patients due to a lack of resources or insufficient health insurance coverage, which results in improper medication and therapies that impede the market growth for allergic asthma treatment. Due to certain concern such as affordability and insurance coverage, many physicians did not prescribe expensive and treatment for allergic asthma which causes a restriction on the utilization of specific therapies, which affect the growth of the overall allergic asthma treatment market. Thus, these are some factors that restrain the market growth.

REPORT COVERAGE

SEGMENTAL ANALYSIS

By Medication Insights

Based on medication, the long-term control medication segment dominates the market at growing at the highest CAGR during the forecasted period. This segment accounted for the largest share 64.05% in 2024. The increasing prevalence of asthma is expected to drive the market growth of this segment during the forecast period. The people with asthma need long-term controller drugs that must be taken daily, asthma exacerbations are majorly prevented by controller medication which reduces chronic inflammation thus this is the longest segment based on medication dominating the market during the forecasted period.

Quick relief medication is also expected to dominate the market during the forecasted period. This medication uses for the acute asthma, these are short-term drugs that include inhalers, which are used to treat chest tightness, and shortness of breath these are quick reliever thus many patients who need daily medication prefer the quick relief medication thus this segment also dominate the market during the forecasted period.

By Route of Administration Insights

Based on the route of administration, Inhalers are expected to dominate the market at the highest CAGR during the forecasted period. Inhalers accounted for the largest market share over 74.06% in 2024, and expected to continue during the forecasted period. Inhalers are the most common and effective way to get asthma medication into the lungs thus this segment dominates the market during the forecasted period.

The prefilled syringe is also expected to dominate the market during the forecasted period. The pandemic situation causes a rise in the demand for the prefilled syringe. The prefilled syringed segment is expected to value at USD 25280 million by 2028.

By Adjunct Therapy Insights

Based on adjunct therapy, the long-acting beta antagonistic segment garnered a market share of 65.3% in 2024 and is projected to reach with a CAGR of 5.2% during the forecast period of 2024 to 2029. This Adjunct is used with a longer duration of action and this medication is used for symptom prevention and used to prevent asthma attacks, Thus this segment is expected to dominate the market during the forecasted period. Long-acting muscarinic antagonistic is also expected to dominate the market at a healthy CAGR during the forecasted period.

By Distribution Channel Insights

Based on the distribution channel, the online pharmacies are expected to dominate the market, this segment accounted for the largest revenue around 43.2% in 2024, and this segment is projected to reach a CAGR of 5.8% during the forecasted period. The pandemic situation strengthened the digital commerce platform which sustained the rapid growth of online pharmacies thus this segment is expected to dominate the market during the forecasted period.

Hospital pharmacies have more opportunities to dominate the market during the forecasted period. This segment is projected to reach a CAGR of 2.08% during the forecasted period 2023-2028. Breathing complications associated with novel coronavirus boosted the hospital pharmacies.

REGIONAL ANALYSIS

Based on region, the North American segment is expected to dominate the market during the projected period. This segment is expected to reach a CAGR of 3.05% over the forecasted period. The presence of major biopharmaceutical companies, Greater awareness of advanced and efficient asthma therapeutics drive the market growth in this region

Europe is the second largest region that dominates the allergic asthma therapeutics market. Asthma is the most common non-communicable disease among the adults and children, thus for the proper diagnosis and treatment needs advanced therapeutics thus this segment also dominates the market with a healthy CAGR of 4.5% over the projected period.

Asia-pacific region is anticipated to show the fastest growth during the projected period, and the increasing presence of key products in this region is anticipated to drive the demand for the asthma allergic therapeutic market.

The increasing prevalence of chronic respiratory diseases, increase in pollution levels, and launches of key products such as generic therapeutics for asthma fuel the market demand in Latin America, middle-east and Africa during the forecasted period.

KEY MARKET PLAYERS

The worldwide prominent key player in the allergic asthma market are

• Aslan Pharmaceuticals Pte. Ltd.
• Axikin Pharmaceuticals, Inc.
• Baxalta Incorporated
• Chiesi Farmaceutici SpA
• Circassia Pharmaceutical Plc
• CSL Limited
• Fountain Biopharma Inc.
• GlaxoSmithKline
• Hydra Biosciences Inc.
• Infinity Pharmaceuticals Inc.
• Kineta Inc.
• Mabtech Limited
• Neopharm Co., Ltd.
• Oxagen Limited

GLOBAL ALLERGIC ASTHMA THERAPEUTIC MARKET NEWS

• In April 2022, The generic asthma medication fluticasone propionate and salmeterol inhalation powder, which is intended for the treatment of asthma and chronic obstructive pulmonary disorder (COPD), has successfully completed phase III clinical research, according to Cipla Inc. This potential candidate is the 100/50 mcg generic version of Advair Diskus.
• In October 2021, The asthma medication Fasenra from AstraZeneca has received regulatory approval for self-administration, according to the U.S. FDA.

MARKET SEGMENTATION

The global allergic asthma therapeutics market research report is segmented and sub-segmented into the following categories.

By Medication

• Quick relief medication
• Long-term control medication

By Route of Administration

• Inhalers
• Prefilled syringes/ vials
• Others

By Adjunct therapy

• Long-acting muscarinic antagonistic
• Long-acting beta Antagonistic
• Others

By Region

• North America
• Latin America
• Europe
• Asia-Pacific
• Middle East and Africa